TOWA PHARMA. CO.
Towa Pharmaceutical Co., Ltd., together with its subsidiaries, manufactures and sale ethical drugs in Japan. It operates through two segments; Domestic and Overseas. The company provides its products in the therapeutic areas of digestive system, nervous system, and allergic diseases, as well as vitamins, antibiotics, and oncology products, as well as provide formulations from Tablets, Capsules, I… Read more
Market Cap & Net Worth: TOWA PHARMA. CO. (6QC)
TOWA PHARMA. CO. (F:6QC) has a market capitalization of $1.10 Billion (€1.07 Billion) as of March 19, 2026. Listed on the F stock exchange, this Germany-based company holds position #10133 globally and #1082 in its home market, demonstrating a -0.91% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying TOWA PHARMA. CO.'s stock price €21.80 by its total outstanding shares 49227897 (49.23 Million).
TOWA PHARMA. CO. Market Cap History: 2021 to 2026
TOWA PHARMA. CO.'s market capitalization history from 2021 to 2026. Data shows growth from $1.10 Billion to $1.10 Billion (8.75% CAGR).
TOWA PHARMA. CO. Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how TOWA PHARMA. CO.'s valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
No P/S ratio data available
Latest Price to Earnings (P/E) Ratio
No P/E ratio data available
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| No financial ratio data available | |||||
Competitor Companies of 6QC by Market Capitalization
Companies near TOWA PHARMA. CO. in the global market cap rankings as of March 19, 2026.
Key companies related to TOWA PHARMA. CO. by market ranking:
- Zoetis Inc (NYSE:ZTS): Ranked #410 globally with a market cap of $53.52 Billion USD.
- Haleon plc (NYSE:HLN): Ranked #434 globally with a market cap of $49.87 Billion USD.
- Takeda Pharmaceutical Co. Ltd. (PINK:TKPHF): Ranked #457 globally with a market cap of $47.47 Billion USD.
- Jiangsu Hengrui Medicine Co Ltd (SHG:600276): Ranked #721 globally with a market cap of $28.19 Billion USD ( CN¥206.84 Billion CNY).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #410 | Zoetis Inc | NYSE:ZTS | $53.52 Billion | $121.68 |
| #434 | Haleon plc | NYSE:HLN | $49.87 Billion | $10.60 |
| #457 | Takeda Pharmaceutical Co. Ltd. | PINK:TKPHF | $47.47 Billion | $30.07 |
| #721 | Jiangsu Hengrui Medicine Co Ltd | SHG:600276 | $28.19 Billion | CN¥55.11 |
TOWA PHARMA. CO. Historical Marketcap From 2021 to 2026
Between 2021 and today, TOWA PHARMA. CO.'s market cap moved from $1.10 Billion to $ 1.10 Billion, with a yearly change of 8.75%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | €1.10 Billion | +12.37% |
| 2025 | €980.30 Million | -3.96% |
| 2024 | €1.02 Billion | +35.57% |
| 2023 | €752.91 Million | -0.67% |
| 2022 | €757.97 Million | -31.35% |
| 2021 | €1.10 Billion | -- |
End of Day Market Cap According to Different Sources
On Mar 18th, 2026 the market cap of TOWA PHARMA. CO. was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $1.10 Billion USD |
| MoneyControl | $1.10 Billion USD |
| MarketWatch | $1.10 Billion USD |
| marketcap.company | $1.10 Billion USD |
| Reuters | $1.10 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.